OTC · CZMWY
Healthcare · Medical - Instruments & Supplies
$36.19
Down-$0.07 (-0.19%)
Updated Oct 13, 2026, 6:51 AM
SID Score
5.2/10
Composite research score
Smart Money
46/100
Neutral
Price performance · CZMWY
1M range · 0 trading sessions · Daily adjusted prices
CZMWY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CZMWY.
Company
Market Activity
Research & News
CZMWY research
Company profile and research snapshot.
CARL ZEISS MEDI UNSP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | BERENBERG | Hold | — |
| Aug 28, 2026 | METZLER EQUITIES | Buy | — |
| Aug 26, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Hold | — |
| Aug 14, 2026 | EQUITA SIM | Hold | — |
| Aug 14, 2026 | DZ BANK | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 6, 2026
ZEISS Medical Technology, one of the world's leading medical technology companies, today announced it will showcase its latest innovations and digital technologies across cataract, corneal refractive, retina, and glaucoma workflows at the American Academy of Ophthalmology (AAO) annual meeting in New Orleans, from Oct. 10-12.
Yahoo · Oct 5, 2026
Investing.com -- Goldman Sachs (ETR: AFXG) (OTC: CZMWY) has downgraded Carl Zeiss Meditec to a Sell rating from its previous Neutral rating, with a revised price target of €23.00 down from €27.00 previously. The analysts say the new target price reflects around 26% downside, while Goldman Sachs’ average upside estimate for the overall European Medtech coverage is 22%.
Yahoo · Sep 24, 2026
ZEISS Medical Technology, one of the world's leading medical technology companies, announced expansive developments across its comprehensive ZEISS Retina Workflow at the European Society of Retina Specialists (EURETINA) congress, spanning retinal imaging, surgical visualization, digital workflow technologies and vitreoretinal surgery. The innovations further strengthen ZEISS's ability to support eye care professionals and retina specialists across the continuum of retinal care, from diagnosis an
Yahoo · Sep 23, 2026
Carl Zeiss Meditec has seen its share price fall sharply in recent years, which puts the spotlight firmly on whether the current valuation is still supported by its earnings. For anyone following the stock, the key issue now is how much of that setback is already reflected in what the market is willing to pay for each euro of profit. The share price has declined 80.6% over the past 5 years, which raises the question of how investors are now weighing the business against its earnings...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CZMWY.
